Trials / Completed
CompletedNCT00929578
Fluphenazine Hydrochloride for Psoriasis
Ascending-Dose, Double-Blind, Placebo-Controlled, Study of Intralesional Fluphenazine Hydrochloride for Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Tufts Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety and biologic activity of intralesional injection of fluphenazine in adult subjects with psoriasis.
Detailed description
This is a double-blind, placebo-controlled, bilateral, ascending dose study. In vitro, fluphenazine has been shown to suppress growth of proliferating T-lymphocytes. Fluphenazine would be expected to also suppress growth of proliferating T-lymphocytes in psoriatic plaques.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluphenazine | Intralesional injection of Fluphenazine |
| DRUG | Placebo | Intralesional injection of placebo |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2010-11-01
- Completion
- 2011-01-01
- First posted
- 2009-06-29
- Last updated
- 2017-03-31
- Results posted
- 2016-08-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00929578. Inclusion in this directory is not an endorsement.